Effect of the Neurokinin 3 Receptor Antagonist Fezolinetant on Patient-reported Outcomes in Postmenopausal Women with Vasomotor Symptoms: Results of a Randomized, Placebo-controlled, Double-blind, Dose-ranging Study (VESTA)

Overview

Journal Menopause

Specialty Gynecology & Obstetrics

Date 2020 Aug 10

PMID 32769757

Citations 14

Authors

Nanette Santoro

Arthur Waldbaum

Samuel Lederman

Robin Kroll

Graeme L Fraser

Christopher Lademacher

Laurence Skillern

James Young

Steven Ramael

Affiliations

Soon will be listed here.

Abstract

Objective: In the primary analysis of the phase 2b VESTA study, oral fezolinetant reduced frequency and severity of menopausal vasomotor symptoms (VMS) compared with placebo. This secondary analysis evaluates effects of fezolinetant on responder rates and patient-reported outcomes (PROs).

Methods: In this 12-week, double-blind study, postmenopausal women with moderate/severe VMS were randomized to fezolinetant 15, 30, 60, or 90 mg BID or 30, 60, or 120 mg QD or placebo. Proportion of responders was based on reductions in VMS from daily diary records. P values for comparisons between active treatment and placebo were calculated using logistic regression. Changes from baseline in PROs (Menopause-Specific Quality of Life questionnaire, Hot Flash-Related Daily Interference Scale, Greene Climacteric Scale) were conducted using a mixed model for repeated measurements and compared post hoc with published minimally important differences (MIDs).

Results: Of 356 women randomized, 352 were treated and analyzed. A greater proportion of women receiving fezolinetant versus placebo met definitions of response at week 12. For all doses, mean changes from baseline in Menopause-Specific Quality of Life questionnaire VMS scores exceeded the MID (1.2) at weeks 4 (placebo: -1.8; fezolinetant: range, -1.9 to -3.6) and 12 (placebo: -2.3; fezolinetant: range, -2.9 to -4.4). Mean changes in Hot Flash-Related Daily Interference Scale at weeks 4 (placebo: -2.2; fezolinetant: range, -2.5 to -3.8) and 12 (placebo: -2.9; fezolinetant: range, -3.3 to -4.3) exceeded the MID (1.76). Greene Climacteric Scale-VMS domain scores improved for most fezolinetant doses versus placebo (week 4, placebo: -1.7; fezolinetant: range, -2.1 to -3.3; week 12, placebo: -2.1; fezolinetant: range, -2.7 to -3.6).

Conclusions: Oral fezolinetant was associated with higher responder rates than placebo and larger improvements in QoL and other PRO measures, including a reduction in VMS-related interference with daily life.

Citing Articles

FDA approved fezolinetant (Veozah): a critical evaluation of its efficacy and safety for menopausal vasomotor symptoms, calling for prospective research.

Rani P, Zehra D, Mansoor M, Rani P Arch Womens Ment Health. 2024; 27(6):943-946.

PMID: 38478035 DOI: 10.1007/s00737-024-01456-y.

Efficacy and safety of fezolinetant, a neurokinin-3 antagonist, in treating vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis.

Rahman U, Kashif T, Usman M, Rana M, Hasanain M, Anjum M Medicine (Baltimore). 2023; 102(50):e36592.

PMID: 38115258 PMC: 10727556. DOI: 10.1097/MD.0000000000036592.

The menopausal transition period and cardiovascular risk.

Mehta J, Manson J Nat Rev Cardiol. 2023; 21(3):203-211.

PMID: 37752349 DOI: 10.1038/s41569-023-00926-7.

Neurokinin receptor antagonists as potential non-hormonal treatments for vasomotor symptoms of menopause.

Conklin M, Santoro N Ther Adv Reprod Health. 2023; 17:26334941231177611.

PMID: 37388717 PMC: 10302519. DOI: 10.1177/26334941231177611.

Menopausal Hormone Therapy in Older Women: Examining the Current Balance of Evidence.

David P, Sobel T, Sahni S, Mehta J, Kling J Drugs Aging. 2023; 40(8):675-683.

PMID: 37344689 DOI: 10.1007/s40266-023-01043-3.

References

Jayasena C, Comninos A, Stefanopoulou E, Buckley A, Narayanaswamy S, Izzi-Engbeaya C . Neurokinin B administration induces hot flushes in women. Sci Rep. 2015; 5:8466. PMC: 4329553. DOI: 10.1038/srep08466. View

DiBonaventura M, Chandran A, Hsu M, Bushmakin A . Burden of vasomotor symptoms in France, Germany, Italy, Spain, and the United Kingdom. Int J Womens Health. 2013; 5:261-9. PMC: 3668089. DOI: 10.2147/IJWH.S39027. View

Radtke J, Terhorst L, Cohen S . The Menopause-Specific Quality of Life Questionnaire: psychometric evaluation among breast cancer survivors. Menopause. 2010; 18(3):289-95. PMC: 3017657. DOI: 10.1097/gme.0b013e3181ef975a. View

Gartoulla P, Bell R, Worsley R, Davis S . Moderate-severely bothersome vasomotor symptoms are associated with lowered psychological general wellbeing in women at midlife. Maturitas. 2015; 81(4):487-92. DOI: 10.1016/j.maturitas.2015.06.004. View

Hilditch J, Lewis J, Peter A, van Maris B, Ross A, Franssen E . A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas. 1996; 24(3):161-75. DOI: 10.1016/s0378-5122(96)82006-8. View

Depypere H, Timmerman D, Donders G, Sieprath P, Ramael S, Combalbert J . Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial. J Clin Endocrinol Metab. 2019; 104(12):5893-5905. DOI: 10.1210/jc.2019-00677. View

Freeman E, Ensrud K, Larson J, Guthrie K, Carpenter J, Joffe H . Placebo improvement in pharmacologic treatment of menopausal hot flashes: time course, duration, and predictors. Psychosom Med. 2015; 77(2):167-75. PMC: 4333078. DOI: 10.1097/PSY.0000000000000143. View

Utian W . Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes. 2005; 3:47. PMC: 1190205. DOI: 10.1186/1477-7525-3-47. View

Bushmakin A, Abraham L, Pinkerton J, Cappelleri J, Mirkin S . Evaluation of the measurement model and clinically important differences for menopause-specific quality of life associated with bazedoxifene/conjugated estrogens. Menopause. 2014; 21(8):815-22. DOI: 10.1097/GME.0000000000000176. View

10.

Carpenter J . The Hot Flash Related Daily Interference Scale: a tool for assessing the impact of hot flashes on quality of life following breast cancer. J Pain Symptom Manage. 2001; 22(6):979-89. DOI: 10.1016/s0885-3924(01)00353-0. View

11.

Mittelman-Smith M, Williams H, Krajewski-Hall S, McMullen N, Rance N . Role for kisspeptin/neurokinin B/dynorphin (KNDy) neurons in cutaneous vasodilatation and the estrogen modulation of body temperature. Proc Natl Acad Sci U S A. 2012; 109(48):19846-51. PMC: 3511761. DOI: 10.1073/pnas.1211517109. View

12.

Rance N, Young 3rd W . Hypertrophy and increased gene expression of neurons containing neurokinin-B and substance-P messenger ribonucleic acids in the hypothalami of postmenopausal women. Endocrinology. 1991; 128(5):2239-47. DOI: 10.1210/endo-128-5-2239. View

13.

Greene J . Constructing a standard climacteric scale. Maturitas. 1998; 29(1):25-31. DOI: 10.1016/s0378-5122(98)00025-5. View

14.

Dacks P, Krajewski S, Rance N . Activation of neurokinin 3 receptors in the median preoptic nucleus decreases core temperature in the rat. Endocrinology. 2011; 152(12):4894-905. PMC: 3230049. DOI: 10.1210/en.2011-1492. View

15.

Rance N, Dacks P, Mittelman-Smith M, Romanovsky A, Krajewski-Hall S . Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol. 2013; 34(3):211-27. PMC: 3833827. DOI: 10.1016/j.yfrne.2013.07.003. View

16.

Williams R, Kalilani L, DiBenedetti D, Zhou X, Fehnel S, Clark R . Healthcare seeking and treatment for menopausal symptoms in the United States. Maturitas. 2007; 58(4):348-58. DOI: 10.1016/j.maturitas.2007.09.006. View

17.

MacLennan A, Broadbent J, Lester S, Moore V . Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004; (4):CD002978. PMC: 7004247. DOI: 10.1002/14651858.CD002978.pub2. View

18.

Avis N, Crawford S, Greendale G, Bromberger J, Everson-Rose S, Gold E . Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015; 175(4):531-9. PMC: 4433164. DOI: 10.1001/jamainternmed.2014.8063. View

19.

Gold E, Sternfeld B, Kelsey J, Brown C, Mouton C, Reame N . Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol. 2000; 152(5):463-73. DOI: 10.1093/aje/152.5.463. View

20.

Lewis J, Hilditch J, Wong C . Further psychometric property development of the Menopause-Specific Quality of Life questionnaire and development of a modified version, MENQOL-Intervention questionnaire. Maturitas. 2005; 50(3):209-21. DOI: 10.1016/j.maturitas.2004.06.015. View